The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG
Completed
Deutsche Stiftung für Herzforschung
Phase 3
2003-06-01
Myocardial dysfunction necessitating inotropic support is a typical complication after
on-pump cardiac surgery. This prospective, randomized pilot-study analyses the metabolic and
renal effects of the inotropes adrenaline and milrinone in patients needing inotropic support
after coronary-artery-bypass-grafting. With respect to data derived from patients with sepsis
shock and results from studies using phosphodiesterase-inhibitors prophylactically, the
hypothesis is tested that adrenaline may be associated with unwarranted metabolic effects
(hyperlactatemia and hyperglycemia) and renal dysfunction.
The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG
Completed
University of Luebeck
Phase 3
2003-06-01
Myocardial dysfunction necessitating inotropic support is a typical complication after
on-pump cardiac surgery. This prospective, randomized pilot-study analyses the metabolic and
renal effects of the inotropes adrenaline and milrinone in patients needing inotropic support
after coronary-artery-bypass-grafting. With respect to data derived from patients with sepsis
shock and results from studies using phosphodiesterase-inhibitors prophylactically, the
hypothesis is tested that adrenaline may be associated with unwarranted metabolic effects
(hyperlactatemia and hyperglycemia) and renal dysfunction.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
N/A
2008-07-01
Many pediatric patients undergoing cardiac surgery under cardiopulmonary bypass for repair of
complex congenital malformations, require inotropic support for low cardiac output syndrome.
Milrinone through its positive inotropic and vasodilatory effects is widely used for this
purpose. The aim of the study is to compare Milrinone with Levosimendan, a novel inotope with
calcium-sensitizing properties. We hypothesized that using Levosimendan would result in
reduced serum lactate through a higher cardiac index.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
